<DOC>
	<DOCNO>NCT02121678</DOCNO>
	<brief_summary>Resistance aerobic exercise show effective maintenance muscle strength patient neuromuscular disease . Exercise CIDP MMN sparsely describe . The aim study evaluate change muscle strength high intensive resistance training change maximal oxygen consumption ( VO2-max ) high intensive aerobic training patient CIDP MMN maintenance therapy subcutaneous immunoglobulin . The hypothesis muscle strength VO2-max significantly increase training session .</brief_summary>
	<brief_title>Effect Resistance Aerobic Exercise CIDP MMN</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Age &gt; 18 &lt; 80 year Diagnosed definite probable CIDP definite probable MMN fulfil European Federation Neurological Sciences/Peripheral Nerve Society ( EFNS/PNS ) criteria Stable maintenance therapy immunoglobulin ( change dosage &lt; 3 month inclusion ) Duration CIDP MMN &gt; 6 month Negative result pregnancy test ( HCGbased assay urine ) woman childbearing potential use reliable method contraception duration study Other cause neuropathy ( incl . pressure neuropathy ) Exercise enrolment ( &gt; 1 hour exercise per week &gt; 4 km bicycle per day ) Walking distance &lt; 10 meter without aid Diabetes mellitus , severe cardiac pulmonary disease , malignancy Known history adverse reaction Immunoglobulin A product Ongoing history hypersensitivity persistent reaction blood plasma derive product . History malignancy lymphoid cell immunodeficiency lymphoma Known liver function impairment ( ALAT 3 time upper limit normal ) Known proteinlosing enteropathy proteinuria . Known renal function impairment ( creatinine &gt; 120 micromol/L creatinine &gt; 1.35 mg/dL ) , predisposition acute renal failure ( e.g. , degree preexist renal insufficiency routine treatment know nephritic drug ) . Treatment investigational medicinal product within 3 month prior first infusion Gammanorm Known suspect HIV , Hepatitis Virus C B infection Pregnant nursing woman Planned pregnancy course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Resistance training</keyword>
	<keyword>Aerobic exercise</keyword>
	<keyword>Isokinetic muscle strength</keyword>
	<keyword>Bicycle ergometry test</keyword>
	<keyword>Subcutaneous immunoglobulin</keyword>
</DOC>